Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library

AZD5004 (elecoglipron, ECC5004): what the evidence says

Name: AZD5004 (elecoglipron, ECC5004)
Published: 2026-10-27

At a glance

What it is: Caution Not a peptide. Elecoglipron is a once-daily oral small-molecule GLP-1 receptor agonist taken without food or fluid restrictions, from AstraZeneca and Eccogene. It is listed here only because it is sold alongside research peptides. ^R1

What the evidence says: Human in the VISTA phase 2 trial (310 adults with obesity or overweight, no diabetes), weight at week 26 fell 2.6% to 10.5% depending on dose vs 0.6% with placebo. ^R1 A phase 1 study found food did not meaningfully change blood levels. ^R2

Biggest risks: GI effects (nausea, constipation, diarrhea, vomiting); 25% of VISTA participants did not complete assigned treatment. ^R1

Rating


Human Human evidence	Moderate: VISTA phase 2 RCT, n = 310 ^R1
Animal Animal / lab evidence	Not reviewed
Regulatory	Investigational · not FDA-approved · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page ^{R3, R4, R5} · not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances) ^R6
Established human dose	No

Evidence verdict: Weight loss: Moderate (one 36-week phase 2 RCT, n = 310)

This page reports what studies used. It is not dosing advice.

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

About the evidence: one well-run, double-blind, placebo-controlled phase 2 trial, funded by the sponsor. No phase 3 data yet.

What is it?

Related pages: ct-996, orforglipron, semaglutide, ct-388.

Does it work?

Human VISTA: −2.6% to −10.5% weight at 26 weeks vs −0.6%; 40–89% lost at least 5% vs 16% on placebo. ^R1
Human Phase 1b in Chinese adults completed. ^R7

Is it safe?

Human Adverse events in 84–98% across doses vs 84% on placebo, mostly GI. ^R1
Human Half-life about 21 hours. ^R2

Pipeline status (investigational)

Sponsor: AstraZeneca (licensed from Eccogene). ^R1
Trials: NCT06579092 VISTA (completed) ^R8; NCT06988553 (completed). ^R7
Expected readouts: VISTA authors say results support phase 3. ^R1 UNVERIFIED phase 3 trial IDs and dates.

Gray-market vials: extra risks

A gray-market vial has no quality control and no guarantee of identity, strength or sterility. We test retail vials blind under the Open Peptide Standard; see /tests/. A passing test covers one batch on one date and does not mean the compound is safe.

Is it legal?

US: not FDA-approved; no Drugs@FDA application found (openFDA searched Oct 27, 2026).
Compounding: not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page. ^{R3, R4, R5}
Sport: not named on WADA's 2026 list; as a drug not approved anywhere for human use it falls under S0 (non-approved substances) ^R6.

Study details

These are amounts researchers used, not recommendations.

Study	People / model	Route	Amount used	Follow-up	Reported	Citation
VISTA phase 2 (Davies 2026)	310 adults, obesity/overweight	Oral daily	5, 15, 50 or 75 mg	36 weeks (primary at 26)	−2.6% to −10.5% vs −0.6%	PMID 42259337
Phase 1 PK (Xu 2026)	14 healthy adults	Oral	50 mg single dose	Single dose	Fed vs fasted exposure similar	PMID 42896872

Full reference list (PubMed, CT.gov, FDA and WADA checked Oct 27, 2026)

^R1 Davies MJ, et al. Lancet. 2026. PMID 42259337
^R2 Xu J, et al. Br J Clin Pharmacol. 2026. PMID 42896872
^R3 FDA, 503A bulk drug substances categories list (updated May 14, 2026). https://www.fda.gov/media/94155/download
^R4 FDA, 503B bulk drug substances categories list (updated Mar 21, 2025). https://www.fda.gov/media/94164/download
^R5 FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current Apr 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
^R6 WADA. The 2026 Prohibited List, S0 Non-approved substances. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
^R7 ClinicalTrials.gov NCT06988553, phase 1b in Chinese adults, Eccogene, completed (CT.gov API v2, checked Oct 27, 2026). https://clinicaltrials.gov/study/NCT06988553
^R8 ClinicalTrials.gov NCT06579092, VISTA phase 2, AstraZeneca, completed (CT.gov API v2, checked Oct 27, 2026). https://clinicaltrials.gov/study/NCT06579092

Disclaimer

This page is for education and harm reduction, not medical advice or a recommendation to use AZD5004 (elecoglipron, ECC5004). This is an investigational drug. It is available only inside registered clinical trials; products sold online under this name are unregulated. Report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).